ASCO 2013: June 4th Wrap-Up

The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.

In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence

The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.

Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.

Pharmacy students can create greater career optionality by viewing the PharmD as a professional platform rather than a predetermined job title.

FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.